entertainment -WSS

entertainment

author：comprehensive 2025-09-27 07:51:43 - browse：6124

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Statins reduce cardiovascular risk in people living with HIV

WSS

How a key Senate committee is planning to regulate PBMs

New requirements coming in 2024 for Americans traveling to Europe

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Where does female orgasm come from? Scientists think they know

Palantir health business leans on meeting customers’ needs

Petition to FDA: Get the lead out of consumer hair dyes

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Walensky prepares to leave CDC — and Congress — behind

Retired US general questions alleged Putin, Prigozhin meeting

Hollywood unions extend contract negotiations for actors

Malaysia cuts short music fest after British band slams anti

Hepatitis C has a cure — but many Americans still lack access to it

Lecanemab for Alzheimer's is coming. Is the health system ready?

Wildfire smoke exposes gaps in outdoor worker protections

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Supreme Court strikes down use of affirmative action

Biden launches a new push to limit health care costs

focus

My chronic pain journey would have been easier knowing 5 things % STAT

Beach reads and more: STAT's 2023 summer book list

The response to Covid

Petition to FDA: Get the lead out of consumer hair dyes

Petition to FDA: Get the lead out of consumer hair dyes

Iowa House, Senate pass 6

hotspot

focus

focus

hotspot